Mird-226 -

The versatility of MIRD-226 has sparked significant interest in its potential medical applications. Some of the areas where MIRD-226 is being explored include:

MIRD-226 works by binding to somatostatin receptors on the surface of NET cells. Once bound, the radiopharmaceutical is internalized by the cell, where the Lu-177 isotope emits beta particles that damage the tumor cells. This results in the death of the tumor cells, while minimizing damage to surrounding healthy tissues. MIRD-226

The key thematic elements include: